The board of directors of Genzyme Corp has rejected Sanofi-Aventis’s unsolicited bid for the company at $69 per share saying that it undervalues the company and its late-stage pipeline which includes a promising new product for multiple sclerosis. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
